SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat
SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now.
Springworks Therapeutics Inc. (SWTX)
This company is not actively trading or the ticker does belong to another company in our database now.
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | Hudson Bay Capital Management Sander Gerber | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | 0 | $0 | 0% | ||
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 50,000 | $900,000.00 | 4,593,847 | 2019-09-17 | Filing | |
| $18.00 | 275,000 | $4,950,000.00 | 7,406,307 | 2019-09-17 | Filing | |
| $18.00 | 275,000 | $4,950,000.00 | 7,406,307 | 2019-09-17 | Filing | |
| $18.00 | 150,000 | $2,700,000.00 | 7,281,307 | 2019-09-17 | Filing | |
| $18.00 | 50,000 | $900,000.00 | 4,593,847 | 2019-09-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $56.20 | 400 | $22,481.00 | 169,712 | 2025-03-03 | Filing | |
| $55.12 | 3,598 | $198,330.76 | 170,112 | 2025-03-03 | Filing | |
| $54.26 | 12,078 | $655,330.54 | 173,710 | 2025-03-03 | Filing | |
| $53.12 | 3,924 | $208,449.94 | 185,788 | 2025-03-03 | Filing | |
| $56.89 | 600 | $34,134.00 | 954,869 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 83 | $3,899 | 0% | |
| 2. | 40,000 | $2,156 | 0% | |
| 3. | 1 | $47 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
SpringWorks Therapeutics (SWTX) Surged on Acquisition News
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Tanya, and I will be your conference operator today.